Baillie Gifford & CO Denali Therapeutics Inc. Transaction History

Baillie Gifford & CO

  • $131 Billion
  • Q3 2024

A detailed history of Baillie Gifford & CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 13,345,887 shares of DNLI stock, worth $323 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
13,345,887
Previous 13,763,596 3.03%
Holding current value
$323 Million
Previous $320 Million 21.64%
% of portfolio
0.3%
Previous 0.25%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024
SELL
$20.96 - $31.05 $8.76 Million - $13 Million
-417,709 Reduced 3.03%
13,345,887 $389 Million
Q2 2024

Jul 25, 2024
SELL
$14.96 - $23.22 $4.15 Million - $6.45 Million
-277,632 Reduced 1.98%
13,763,596 $320 Million
Q1 2024

May 01, 2024
SELL
$15.83 - $23.35 $3.47 Million - $5.13 Million
-219,496 Reduced 1.54%
14,041,228 $288 Million
Q4 2023

Jan 26, 2024
SELL
$16.2 - $23.18 $6.81 Million - $9.74 Million
-420,303 Reduced 2.86%
14,260,724 $306 Million
Q3 2023

Nov 13, 2023
SELL
$20.63 - $30.17 $3.36 Million - $4.91 Million
-162,743 Reduced 1.1%
14,681,027 $303 Million
Q2 2023

Jul 28, 2023
SELL
$23.37 - $32.96 $11.9 Million - $16.8 Million
-508,341 Reduced 3.31%
14,843,770 $438 Million
Q1 2023

May 03, 2023
BUY
$21.91 - $32.67 $5.1 Million - $7.6 Million
232,637 Added 1.54%
15,352,111 $354 Million
Q4 2022

Jan 24, 2023
BUY
$26.28 - $33.92 $10.6 Million - $13.7 Million
404,423 Added 2.75%
15,119,474 $420 Million
Q3 2022

Oct 27, 2022
SELL
$25.97 - $38.53 $4.01 Million - $5.95 Million
-154,323 Reduced 1.04%
14,715,051 $452 Million
Q2 2022

Aug 08, 2022
SELL
$20.88 - $35.19 $2.32 Million - $3.91 Million
-111,058 Reduced 0.74%
14,869,374 $438 Million
Q1 2022

May 05, 2022
SELL
$29.0 - $47.27 $2.2 Million - $3.59 Million
-75,949 Reduced 0.5%
14,980,432 $482 Million
Q4 2021

Jan 20, 2022
BUY
$42.59 - $55.02 $1.98 Million - $2.56 Million
46,565 Added 0.31%
15,056,381 $672 Million
Q3 2021

Oct 19, 2021
SELL
$48.48 - $78.23 $6.68 Million - $10.8 Million
-137,797 Reduced 0.91%
15,009,816 $757 Million
Q2 2021

Aug 02, 2021
BUY
$50.3 - $78.44 $108 Million - $169 Million
2,152,416 Added 16.56%
15,147,613 $1.19 Billion
Q1 2021

May 06, 2021
BUY
$53.8 - $81.53 $43.3 Million - $65.6 Million
804,941 Added 6.6%
12,995,197 $742 Million
Q4 2020

Feb 10, 2021
BUY
$36.89 - $93.56 $50.3 Million - $128 Million
1,363,078 Added 12.59%
12,190,256 $1.02 Billion
Q3 2020

Nov 12, 2020
BUY
$23.13 - $38.84 $35.8 Million - $60.1 Million
1,547,984 Added 16.68%
10,827,178 $388 Million
Q2 2020

Aug 12, 2020
BUY
$16.01 - $28.82 $2.39 Million - $4.31 Million
149,442 Added 1.64%
9,279,194 $224 Million
Q1 2020

May 08, 2020
BUY
$14.2 - $27.98 $21.9 Million - $43.1 Million
1,539,505 Added 20.28%
9,129,752 $160 Million
Q4 2019

Feb 10, 2020
BUY
$14.4 - $19.99 $3.27 Million - $4.53 Million
226,784 Added 3.08%
7,590,247 $132 Million
Q3 2019

Nov 07, 2019
SELL
$15.32 - $21.92 $670,495 - $959,350
-43,766 Reduced 0.59%
7,363,463 $113 Million
Q2 2019

Aug 08, 2019
BUY
$18.5 - $28.14 $21.2 Million - $32.2 Million
1,145,003 Added 18.28%
7,407,229 $154 Million
Q1 2019

May 01, 2019
BUY
$17.99 - $24.65 $620,690 - $850,474
34,502 Added 0.55%
6,262,226 $0
Q4 2018

Feb 14, 2019
BUY
$13.88 - $21.75 $10.3 Million - $16.1 Million
741,303 Added 13.51%
6,227,724 $129 Million
Q3 2018

Nov 13, 2018
BUY
$12.46 - $21.74 $1.77 Million - $3.08 Million
141,788 Added 2.65%
5,486,421 $119 Million
Q2 2018

Jul 17, 2018
BUY
$15.25 - $21.02 $2.31 Million - $3.19 Million
151,787 Added 2.92%
5,344,633 $81.5 Million
Q1 2018

May 10, 2018
BUY
$15.36 - $24.8 $4.16 Million - $6.72 Million
271,063 Added 5.51%
5,192,846 $102 Million
Q4 2017

Feb 13, 2018
BUY
$15.04 - $21.45 $74 Million - $106 Million
4,921,783
4,921,783 $77 Million

Others Institutions Holding DNLI

# of Institutions
228
Shares Held
120M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.24B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email